Trimethoprim-Sulfamethoxazole and Acute Respiratory Failure in Adolescents and Young Adults.

ABSTRACT:

Importance

The US Food and Drug Administration (FDA) has issued a warning and a label change regarding a potential association between trimethoprim-sulfamethoxazole (TMP-SMX) and acute respiratory failure in healthy adolescents and young adults.

Objective

To examine the 30-day risk of a hospital visit (ie, hospitalization or emergency department visit) with acute respiratory failure in adolescents and young adults aged 10 to younger than 25 years old newly dispensed oral TMP-SMX compared with new users of amoxicillin or a cephalosporin.

Design, setting, and participants

This retrospective, population-based, new-user cohort study in Ontario, Canada (2003-2023) used linked administrative health care data. The TMP-SMX vs amoxicillin and TMP-SMX vs cephalosporins cohorts

SUBMITTER: Ahmadi F 

PROVIDER: S-EPMC12645330 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature